
BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.
National report - Although the training of D.O. dermatologists and their M.D. counterparts differs somewhat, these paths are converging to the point that many sources say both are equally rigorous. But while acceptance of D.O. dermatologists in the M.D. community is increasing, pockets of resistance remain, they add.






